Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Account Payables (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Change in Account Payables for 7 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 195.25% to -$1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.0 million, a 543.0% decrease, with the full-year FY2025 number at -$2.0 million, down 543.0% from a year prior.
  • Change in Account Payables was -$1.5 million for Q4 2025 at Kymera Therapeutics, down from -$267000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.2 million in Q3 2022 to a low of -$4.1 million in Q2 2025.
  • A 5-year average of $3200.0 and a median of -$206000.0 in 2021 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 5122.67% in 2025; the steepest drop was 13432.26% in 2025.
  • Kymera Therapeutics' Change in Account Payables stood at -$1.0 million in 2021, then crashed by 101.17% to -$2.1 million in 2022, then surged by 174.03% to $1.5 million in 2023, then plummeted by 132.98% to -$505000.0 in 2024, then crashed by 195.25% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Change in Account Payables are -$1.5 million (Q4 2025), -$267000.0 (Q3 2025), and -$4.1 million (Q2 2025).